Mode
Text Size
Log in / Sign up
N/A N=22 Treatment

Mobile Technology for Reducing and Preventing Adolescent Suicide

Suicide, Attempted · Suicidal Ideation

Enrolled (actual)
22
Serious AEs
40.9%
Results posted
Mar 2023
Primary outcome: Primary: App Usability 1 Week — 83.948 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Smartphone App (Behavioral)
Age
Pediatric · 13+ yrs
Sex
All
Sponsor
Hartford Hospital
Primary completion
May 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
App Usability 1 Week
83.948
PRIMARY
App Usability 4 Weeks
86.875
PRIMARY
App Usability 8 Weeks
85.500
PRIMARY
App Usability 12 Weeks
86.833
PRIMARY
App Usability 16 Weeks
85.625
SECONDARY
Suicidal Ideation Baseline
54.700
SECONDARY
Suicidal Ideation 1 Week
43.421
SECONDARY
Suicidal Ideation 4 Weeks
27.125
SECONDARY
Suicidal Ideation 8 Weeks
25.200
SECONDARY
Suicidal Ideation 12 Weeks
26.867
SECONDARY
Suicidal Ideation 16 Weeks
26.625

Summary

This single-group open-label trial will evaluate the feasibility and preliminary efficacy of a suicide prevention mobile application when used as an adjunct to usual care in adolescents.

Eligibility Criteria

Inclusion Criteria

  • Inpatient psychiatric patients who have attempted suicide (lifetime) or have documented suicide ideation and a plan to harm themselves at admission
  • Understand written and spoken English
  • Own an iPhone with iOS 11 or higher, or Android with OS 8.1 or higher
  • Willing and able to complete enrollment procedures
  • Parent/guardian (and youth) able to understand the nature of the study and provide written informed consent (assent for youth)
  • Willing to agree to release of information to their parent/guardian and providers when clinically indicated.
  • Discharge plan includes aftercare within the Hartford HealthCare system (to facilitate coordination of care during follow up)

Exclusion Criteria

  • Patients with active psychosis
  • Patients experiencing substance withdrawal
  • Currently enrolled in other treatment studies for the symptoms and behaviors targeted
  • Patient unwilling or unable to wear mask during in-person study procedures
  • Patients who, in the judgment of the investigator, would have an unfavorable risk/benefit profile with respect to the Smartphone App.
  • Any other psychiatric or medical condition (e.g., intellectual disability) or custody arrangement that in the investigator's opinion would preclude informed consent/assent or participation in the trial.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04896593). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search